A peer-reviewed study of loss-of-function variants in WDFY3 found varied developmental features in people. Lithium chloride increased gene expression in cultured cells and branching in mouse neurons. The work did not test whether that cellular change becomes a safe or useful treatment in people. Keeping the clinical observations separate from the laboratory experiment is central to understanding what families can take from the result.
The newly described WDFY3 cases showed developmental features, but their clinical pictures were not identical. Head measurements differed, and some parents carrying inherited variants had mild or no visible features. The Molecular Psychiatry paper therefore gives families a pattern without making one genetic finding a fixed forecast for every carrier. Its clinical value lies in describing both the recurring features and the range within which they appear.[1]
In nerve-related human cells with WDFY3 experimentally suppressed, protein aggregates were cleared less effectively and cell extensions were shorter. In separate work, lithium chloride raised WDFY3 expression in culture and branching in mouse neurons. These observations help identify a biological route to investigate. They supply no dose, delivery approach or safety result for treating children. A response in isolated cells is a different outcome from improved development in a person.[1]
The clinical observations and the branching response sit in the same research programme, but a clinical bridge between them has yet to be built. The paper reports no benefit or harm in people given lithium for WDFY3. It also leaves the route behind the branching response in mouse neurons unresolved. For families, the practical distinction is clear: this is a reason to investigate a possible intervention, not evidence that the intervention already helps an affected child.[1]
